On 8 October 2026, Genetic Signatures Limited (ASX:GSS) released its Quarterly Activities Report and Appendix 4C for the first quarter of FY2027. The company reported cash and term deposits of A$20.9 million with no debt, and net operating cash outflow of A$1.0 million.

Cash flow and cost base

Cash and term deposits at 30 September 2026 were A$20.9 million, made up of A$7.9 million in cash and A$13.0 million in term deposits. Net operating cash outflow was A$1.0 million, compared with A$3.4 million in Q4 FY2026 (A$2.6 million excluding one-off redundancy payments) and A$2.1 million in Q1 FY2026.

Operating expenses, excluding cost of materials, were A$4.0 million, 30% lower than A$5.7 million in Q1 FY2026, in the first full quarter after the Q4 FY2026 restructure. Staff costs were A$2.5 million. The company said it is on a path to annualised operational cost savings of up to A$5 million, and that quarterly outflows are expected to vary as a result of one-off product development costs and seasonal changes in revenue. Sales were A$4.0 million (unaudited), compared with A$5.4 million in Q1 FY2026, and receipts from customers were A$4.2 million.

Proposed Merger with Microba Life Sciences

In September 2026, the company agreed the principal commercial terms of a proposed all-scrip merger with Microba Life Sciences Limited, to be implemented by a scheme of arrangement. Microba shareholders would receive 0.654 new GSS shares for each Microba share and hold about 67% of the combined group.

The release states that on a pro forma basis the combined group would have about A$29.6 million of FY2026 revenue, about A$30 million of cash and term deposits and net Assets of about A$60.1 million, with estimated annualised gross cost synergies of A$2.5 million to A$3.0 million. The merger remains subject to conditions, including GSS Shareholder approval.

Customer and APAC developments

Validation was completed and commercial testing began in August 2026 at Hvidovre Hospital in Denmark under a ten-year Supply agreement signed in April 2026. In India, the company has started negotiations with a local distributor and signed an MOU with a manufacturer of CE-IVD products, and in Hong Kong it has signed a confidentiality agreement with a distributor and is completing due diligence.

Extraordinary General Meeting

GSS called an Extraordinary General Meeting for 28 October 2026 in response to requisition notices served by BCAL Diagnostics Limited. Resolutions 1 to 4 seek to appoint two directors and remove two current directors.

Sector backdrop

Appendix 4C is a quarterly Cash Flow report required of listed entities that are not yet profitable or cash-flow positive. It shows receipts, payments and cash balances for the quarter and is a key source of information on a company’s funding runway.

Mergers between small listed healthcare companies are often structured as scrip schemes, and shareholders of both companies typically vote. Requisitioned meetings are a mechanism shareholders can use to propose board changes.

Risks shareholders should weigh

Sales of A$4.0 million were lower than the A$5.4 million recorded in Q1 FY2026. The decline in cash outflow was primarily from restructuring, and the company said quarterly outflows may vary with one-off product development costs and seasonal revenue.

The proposed merger has not been completed and is subject to conditions, including GSS shareholder approval. Microba holders would own about 67% of the combined group, so existing GSS holders would be diluted to about 33%. The requisitioned EGM on 28 October 2026 could change the board before then.

Expansion in India and Hong Kong is at an early stage, with negotiations, an MOU and Due Diligence rather than signed distribution agreements. Several figures are unaudited.

What’s next

The EGM is due on 28 October 2026, and the merger with Microba remains subject to conditions and a shareholder vote. The company said it is progressing APAC distribution discussions and the Hvidovre Hospital contract. Shareholders may wish to watch for scheme documents, the EGM outcome and the next quarterly report.